Experience

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coherus BioSciences, Inc. of $200 million aggregate principal amount of its…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Natera, Inc. of $287.5 million aggregate principal amount of its 2.25%…

Davis Polk advised the sole book-running manager in connection with the SEC-registered offering by Nevro Corp. of $189.75 million aggregate principal amount of its 2.75% convertible…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 16,000,000 shares of common stock…

Davis Polk advised the underwriters in connection with Alector, Inc.’s $240 million public offering of 9,602,500 shares of common stock, which includes the 1,252,500 shares offered pursuant…

Davis Polk advised the joint book-running managers for the public offering of common stock by Ardelyx, Inc for gross proceeds of approximately $144 million, including the full exercise…

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes…

Davis Polk advised the several underwriters in connection with the follow-on offering of 6,571,428 shares of common stock of Natera, Inc. for total gross proceeds of approximately $230…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the follow-on offering of 5,227,272 shares of common stock of Allakos Inc. for…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering of common stock by Seattle Genetics, Inc. for gross…